Top 5 Drug Type | Count |
---|---|
Prophylactic vaccine | 3 |
Therapeutic vaccine | 3 |
Monoclonal antibody | 2 |
Antibody drug conjugate (ADC) | 1 |
Bispecific antibody | 1 |
Target |
Mechanism IFNAR agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism β-galactosidase modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jun 2025 |
Sponsor / Collaborator |
Start Date01 Feb 2025 |
Sponsor / Collaborator |
Start Date01 Nov 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Interferon-α2b(University Hospital Tuebingen) ( IFNAR ) | Melanoma More | Phase 3 |
CoVac-1 ( SARS-CoV-2 S protein ) | COVID-19 More | Phase 2 Clinical |
Peptide vaccine IPX(University Hospital Tuebingen) | - | Phase 2 Clinical |
Prime2-CoV-Delta ( SARS-CoV-2 N protein x SARS-CoV-2 S protein ) | COVID-19 More | Phase 1 |
Multipeptide Vaccine(University Hospital Tuebingen) | Glioblastoma Multiforme More | Phase 1 |